Louisiana 2019 2019 Regular Session

Louisiana House Bill HB526 Comm Sub / Analysis

                    DIGEST
The digest printed below was prepared by House Legislative Services.  It constitutes no part of the
legislative instrument.  The keyword, one-liner, abstract, and digest do not constitute part of the law
or proof or indicia of legislative intent.  [R.S. 1:13(B) and 24:177(E)]
HB 526 Original	2019 Regular Session	Hoffmann
Abstract:  Adds requirements for medical assistance program coverage of opioid use disorder
medications by prohibiting certain acts. 
Proposed law  prohibits prior authorization requirements for opioid use disorder by Medicaid and
its managed care organizations for medications of any United States Food and Drug Administration
(FDA) approved treatment for opioid use disorder.
Proposed law prohibits step therapy requirements prior to authorization of coverage by Medicaid and
its managed care organizations for an FDA approved medication used for the treatment of opioid use
disorder.
Proposed law  requires for the listing of all formulations of buprenorphine/naloxone on the La.
Medicaid fee-for-service drug list and the Healthy La. Common Preferred Dug List. 
Proposed law prohibits excluding coverage of prescriptions and services by Medicaid and its
managed care organizations that are based upon court order. 
(Adds R.S. 46:460.37)